Literature DB >> 21555607

Risk factors for visual field progression in treated glaucoma.

Carlos Gustavo V De Moraes1, Viral J Juthani, Jeffrey M Liebmann, Christopher C Teng, Celso Tello, Remo Susanna, Robert Ritch.   

Abstract

OBJECTIVE: To determine intraocular pressure (IOP)-dependent and IOP-independent variables associated with visual field (VF) progression in treated glaucoma.
DESIGN: Retrospective cohort of the Glaucoma Progression Study.
METHODS: Consecutive, treated glaucoma patients with repeatable VF loss who had 8 or more VF examinations of either eye, using the Swedish Interactive Threshold Algorithm (24-2 SITA-Standard, Humphrey Field Analyzer II; Carl Zeiss Meditec, Inc, Dublin, California), during the period between January 1999 and September 2009 were included. Visual field progression was evaluated using automated pointwise linear regression. Evaluated data included age, sex, race, central corneal thickness, baseline VF mean deviation, mean follow-up IOP, peak IOP, IOP fluctuation, a detected disc hemorrhage, and presence of beta-zone parapapillary atrophy.
RESULTS: We selected 587 eyes of 587 patients (mean [SD] age, 64.9 [13.0] years). The mean (SD) number of VFs was 11.1 (3.0), spanning a mean (SD) of 6.4 (1.7) years. In the univariable model, older age (odds ratio [OR], 1.19 per decade; P = .01), baseline diagnosis of exfoliation syndrome (OR, 1.79; P = .01), decreased central corneal thickness (OR, 1.38 per 40 μm thinner; P < .01), a detected disc hemorrhage (OR, 2.31; P < .01), presence of beta-zone parapapillary atrophy (OR, 2.17; P < .01), and all IOP parameters (mean follow-up, peak, and fluctuation; P < .01) were associated with increased risk of VF progression. In the multivariable model, peak IOP (OR, 1.13; P < .01), thinner central corneal thickness (OR, 1.45 per 40 μm thinner; P < .01), a detected disc hemorrhage (OR, 2.59; P < .01), and presence of beta-zone parapapillary atrophy (OR, 2.38; P < .01) were associated with VF progression.
CONCLUSIONS: IOP-dependent and IOP-independent risk factors affect disease progression in treated glaucoma. Peak IOP is a better predictor of progression than is IOP mean or fluctuation.

Entities:  

Mesh:

Year:  2011        PMID: 21555607     DOI: 10.1001/archophthalmol.2011.72

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  84 in total

1.  Prior rates of visual field loss and lifetime risk of blindness in glaucomatous patients undergoing trabeculectomy.

Authors:  W S Foulsham; L Fu; A J Tatham
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

2.  Are rates of vision loss in patients in English glaucoma clinics slowing down over time? Trends from a decade of data.

Authors:  T Boodhna; L J Saunders; D P Crabb
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

3.  [Medicinal glaucoma therapy. What can we learn from large randomized clinical trials?].

Authors:  A G M Jünemann; C Huchzermeyer; R Rejdak
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

4.  Why Do People (Still) Go Blind from Glaucoma?

Authors:  Remo Susanna; Carlos Gustavo De Moraes; George A Cioffi; Robert Ritch
Journal:  Transl Vis Sci Technol       Date:  2015-03-09       Impact factor: 3.283

5.  Thirteen-Year Follow-up of Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study.

Authors:  Donald L Budenz; Julia Beiser Huecker; Steven J Gedde; Mae Gordon; Michael Kass
Journal:  Am J Ophthalmol       Date:  2016-11-07       Impact factor: 5.258

6.  A validated risk calculator to assess risk and rate of visual field progression in treated glaucoma patients.

Authors:  Carlos Gustavo De Moraes; Mitra Sehi; David S Greenfield; Yun S Chung; Robert Ritch; Jeffrey M Liebmann
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-14       Impact factor: 4.799

7.  Elevated intraocular pressure in patients with acromegaly.

Authors:  Luciano Quaranta; Ivano Riva; Gherardo Mazziotti; Teresa Porcelli; Irene Floriani; Andreas Katsanos; Andrea Giustina; Anastasios G P Konstas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-10       Impact factor: 3.117

8.  Relationship of change in central corneal thickness to visual field progression in eyes with glaucoma.

Authors:  Deepa Viswanathan; Ivan Goldberg; Stuart L Graham
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-14       Impact factor: 3.117

9.  Evaluation of baseline structural factors for predicting glaucomatous visual-field progression using optical coherence tomography, scanning laser polarimetry and confocal scanning laser ophthalmoscopy.

Authors:  M Sehi; N Bhardwaj; Y S Chung; D S Greenfield
Journal:  Eye (Lond)       Date:  2012-10-12       Impact factor: 3.775

10.  Evaluation of ocular surface disease in patients with glaucoma.

Authors:  Priya M Mathews; Pradeep Y Ramulu; David S Friedman; Canan A Utine; Esen K Akpek
Journal:  Ophthalmology       Date:  2013-05-25       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.